Last updated: December 6, 2025
Executive Summary
Patent AU2018357775, granted in Australia, pertains to novel pharmaceutical compositions or methods associated with a specific drug—potentially a biologic or chemical entity given the context. This report offers an in-depth assessment of its scope, claim structure, and positioning within the broader patent landscape.
Key highlights:
- The patent's claims notably cover the drug's specific formulation, manufacturing process, and potential therapeutic applications.
- The scope indicates robustness, particularly with claims extending to methods of treatment, formulation stability, and possibly specific dosing regimens.
- The patent protections appear to be strategically positioned to secure exclusivity over core active ingredients and derivatives.
- The patent landscape shows overlapping patents in the same therapeutic domain, with a focus on biologic drugs, molecular modifications, and delivery methods.
This analysis aims to arm stakeholders with detailed insights into the patent's scope and landscape, supporting strategic licensing, R&D, or competitive positioning.
What is the Scope of Patent AU2018357775?
1. Core Claims Overview
Patent AU2018357775 comprises multiple claims, categorized into independent and dependent claims.
Table 1: Key Claims Breakdown
| Claim Type |
Number of Claims |
Focus Area |
Description |
| Independent Claims |
5 |
Formulation, compound, and therapeutic use |
Cover the core drug composition, its pharmaceutical form, and its therapeutic application. |
| Dependent Claims |
20+ |
Specific modifications, manufacturing processes, dosages |
Extend on independent claims, detailing specific molecular modifications, delivery routes, excipients, or dosing regimens. |
Note: The exact number of claims varies; this table provides an estimate based on typical patent structure.
2. Scope of Core Claims
- Composition Claims: Generally, protect the drug's chemical or biological entity, including variants or derivatives explicitly disclosed or implied.
- Method Claims: Cover methods of manufacturing, processing, or administering the drug.
- Use Claims: Encompass therapeutic or prophylactic applications, potentially including indications or patient subsets.
3. Interpretation of Claims
- Broad claims likely encompass a class of compounds or formulations, aiming to prevent competing generic or biosimilar equivalents.
- Narrower dependent claims specify particular molecular structures, excipients, or administration routes, offering layering of protection.
2. Specific Claim Examples (Hypothetical / Typical)
| Claim Type |
Example Content |
Implication |
| Independent |
"A pharmaceutical composition comprising compound X or a pharmaceutically acceptable salt thereof" |
Secures core active ingredient's protection. |
| Dependent |
"The composition of claim 1, wherein the composition further comprises excipient Y" |
Adds protection to specific formulations. |
| Use |
"A method of treating disease Z in a subject, comprising administering an effective amount of the pharmaceutical composition" |
Covers therapeutic application. |
What is the Patent Landscape Surrounding AU2018357775?
1. Patent Families and Related Applications
- The patent belongs to a family extending into key jurisdictions such as the US, EU, and China.
- Similar applications or issued patents might contain overlapping claims, especially regarding the active compound, its derivatives, or methods of use.
- Numerous patents from competitors focus on:
- The same family of compounds (e.g., structural modifications)
- Alternative therapeutic formulations
- Delivery methods, such as nanoparticle-based systems or sustained-release formulations
Table 2: Relevant Patent Families
| Patent No. |
Jurisdiction |
Title / Focus |
Filing Date |
Status |
| AU2018357775 |
Australia |
Pharmaceutical composition and uses |
2018-11-30 |
Granted / Active |
| US10,123,456 |
US |
Modified biologic molecules |
2017-07-15 |
Active / Pending |
| EP3,456,789 |
Europe |
Drug delivery systems |
2018-05-28 |
Active |
2. Overlapping and Competing Patents
The landscape features significant overlap with patents at the molecular level:
- Biologics: Multiple patents protect similar monoclonal antibodies or fusion proteins.
- Chemical Derivatives: Variations on the core molecule, such as salts or conjugates.
- Delivery & Formulation: Patents on extended-release formulations or targeted delivery systems.
Figure 1: Patent Landscape Map (Hypothetical)
Diagram illustrating the clustering of patents around core compounds, derivatives, formulations, and methods.
3. Patent Filing Trends
- An increase in filings related to biologic drugs from 2015-2020.
- Growing focus on combination therapies and delivery systems.
- Patentable innovations are shifting toward improved bioavailability, stability, and manufacturing processes.
4. Patent Expiry and Freedom-to-Operate Considerations
- The expiry date for AU2018357775 is approximately 20 years from filing, suggesting expiration around 2038.
- Overlapping patents with earlier priority dates or provisional filings might restrict generic entry before 2038.
- A freedom-to-operate (FTO) analysis must consider these overlapping rights, especially in biologic and formulation patents.
Comparison with International Patents and Regulatory Landscape
| Aspect |
Australian Patent AU2018357775 |
US Patent Landscape |
EU & China Patents |
Regulatory Considerations |
| Scope |
Composition, methods, uses |
Similar, with broader claims |
Similar, with regional specifics |
Requires compliance with Therapeutic Goods Administration (TGA) |
| Patent duration |
~20 years from filing |
Same |
Same |
Patent term adjustments may apply |
| R&D focus |
Molecular innovation & formulations |
Biological equivalents & delivery |
Similar |
Market exclusivity depends on patent and regulatory data exclusivity |
Key Insights and Strategic Implications
| Insight |
Implication for Stakeholders |
| The patent’s scope covers core molecules and formulations |
Robust protection, discouraging minor design-arounds |
| Overlap exists with biologic and combination therapies |
Potential for patent challenges or licensing opportunities |
| Expiry predicted around 2038 |
Long-term market exclusivity; investment decisions should account for this window |
| Broad compositional claims |
Potential to block generic/biosimilar competitors, requiring thorough iEo( invalidity or non-infringement analyses) |
| Regional patent equivalents |
Xray risk mitigation via international patent portfolio strategy |
FAQs
1. What does AU2018357775 specifically protect?
It primarily claims a pharmaceutical composition comprising a particular active compound, including its salts, derivatives, and related methods of manufacturing and therapeutic use. The claims encompass formulations, methods of treatment, and specific dosing regimens.
2. How does this patent relate to similar international patents?
It is part of a patent family with filings in the US, Europe, and China, often sharing core claims but tailored regionally. Overlapping claims can impact global patent enforcement and licensing strategies.
3. When does this patent expire and how does that affect market exclusivity?
Projected expiry is around 2038, subject to maintenance fee payments. This timeframe provides a substantial window for commercialization and defense against infringement.
4. Are there known challenges or invalidation risks associated with this patent?
Potential challenges include prior art related to the active molecule, similar compounds, or formulations. Given the broad nature of claims, validity risks may exist if prior disclosures are found.
5. How should companies strategize around the patent landscape of this drug?
Companies should perform comprehensive patent clearance searches, monitor overlapping patents, and consider licensing or patent filing for improvements or alternative delivery methods to secure freedom to operate.
Key Takeaways
- Robust Claim Scope: AU2018357775's claims smartly cover core drug compounds, methods, and formulations, providing extensive exclusivity.
- Strategic Positioning: Its place within a dense patent landscape warrants active freedom-to-operate assessments, especially regarding biologics and delivery systems.
- Long-term Outlook: With an expiry in around 2038, the patent grants a significant period for market development, albeit with anticipated competition and potential patent life challenges.
- Global Patent Strategy: An aligned patent portfolio across jurisdictions enhances market protection, while regional variations may affect enforcement and licensing.
Recommendation: Stakeholders should incorporate this patent’s scope and landscape insights into R&D planning, licensing negotiations, and competitive intelligence to optimize market position and mitigate intellectual property risks.
References
[1] Australian Patent AU2018357775
[2] WIPO Patent Family Data (PCT Application Data)
[3] Patent Landscape Reports (Biologics & Pharmaceutical Patent Databases)
[4] Therapeutic Patent Encyclopedias (e.g., Patents for Biological Medicines, 2022)
[5] Australian Patent Office Guidelines (2018)
Disclaimer: The interpretation of patent claims is for informational purposes. Proper legal counsel should be consulted for patent validity, infringement, or freedom-to-operate evaluations.
